Heart failure (HF) disturbs the quality of life (QOL) in patients more intensely than many other chronic diseases. Thus, improving the QOL of patients with HF is equally important as managing the disease. PARADIGM-HF trial highlights the added benefits of sacubitril-valsartan combination over enalapril for improving the QOL and decreasing the rehospitalization episodes in patients with HF. Heart failure needs an appropriate management to improve the QOL in patients.
The pharmacological management of HF includes diuretics, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-adrenergic blockers, aldosterone antagonists, digoxin, anticoagulants, inotropic agents. ACEIs are considered the gold standard in the treatment of HF. However, clinical trials have proved the safety and efficacy of a new combination of sacubitril and valsartan for effectively…
